Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + chidamide
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Brentuximab vedotin + chidamide is a combination therapy regimen being evaluated for the treatment of CD30-positive peripheral T-cell lymphoma (PTCL). The regimen consists of brentuximab vedotin, an antibody-drug conjugate (ADC) that targets CD30-expressing cells to deliver the cytotoxic microtubule-disrupting agent monomethyl auristatin E (MMAE), and chidamide (tucidinostat), an orally available, subtype-selective histone deacetylase (HDAC) inhibitor. Preclinical studies suggest that chidamide synergistically enhances the apoptotic effects of brentuximab vedotin. This specific combination is being studied by The First Affiliated Hospital of Soochow University as an induction and consolidation therapy, followed by chidamide maintenance, particularly for patients who are unfit for standard chemotherapy.
- Other names
- chidamide + brentuximab vedotintucidinostat + brentuximab vedotinbrentuximab vedotin plus chidamide
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)CD30 (CD30 antigen)
Beyond the preview
Go deeper on brentuximab vedotin + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + chidamide.